Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?

Journal Title: OncoReview - Year 2016, Vol 6, Issue 1

Abstract

Authors and Affiliations

Charles Porter

Keywords

Related Articles

Maintenance chemotherapy with pemetrexed in patients with malignant pleural mesothelioma – case series and review of the literature

Malignant pleural mesothelioma is a rare neoplasm with poor prognosis. Surgical complete resection, which is the only radical therapy available, is only possible in a minority of patients who suffer from a locally advanc...

Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group

Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metas...

Liposomal doxorubicin in first line metastatic HER-2-positive breast cancer for prevention the cardiotoxicity

We describe a 62 year old female with metastatic HER-2-positive breast cancer, and with independent cardiovascular comorbidities. She was earlier treated with J131 therapy due to thyroid toxicity. She developed grade 2 m...

“Life-saving” inappropriate implantable cardioverter-defibrillator shocks in a cancer patient

Impaired left ventricular ejection fraction (LV EF) in patients with cancer can disqualify them from targeted antineoplastic treatment. We present the case of 63-year-old male with gastric cancer treated palliatively, wi...

Download PDF file
  • EP ID EP78733
  • DOI 10.5604/20828691.1198514
  • Views 196
  • Downloads 0

How To Cite

Charles Porter (2016). Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?. OncoReview, 6(1), 11-13. https://europub.co.uk/articles/-A-78733